Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Amylyx class action Relyvrio
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $94.80M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.5¢ | $140.9K | 586.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12010 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 70000 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
-0.010 ( 4.08 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.5¢ | 23.5¢ | 164909 | ||
| Last updated 15.58pm 26/04/2024 ? | |||||
| PAA (ASX) Chart |